logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2002 to 2006 — last study available [see all figures in this series...]

Part (i) Estimates of overall problem drug use

Notes:

The term 'problem drug use' is defined in the methods and notes section of the Statistical bulletin.

Methods of estimation are abbreviated: CR=Capture-recapture; TM =Treatment multiplier; PM = Police multiplier; MI = Multivariate indicator; TP= Truncated Poisson; CM = Combined methods; MM= Mortality multiplier; OT= Other methods.

In the case of Cyprus, Germany, Czech Republic, Finland and Spain the line given represents an interval between the lowest lower bound of all existing estimates and the highest upper bound of them.

In the case of Finland, the age range of the study is 15 to 54 years old; Malta: the age range of the study is 12 to 64 years old.

Target groups may vary slightly between countries owing to different methods and data sources; therefore comparisons should be made with caution.

The symbol indicates a point estimate, a bar indicates an uncertainty interval, which can be either a 95 % confidence interval or an interval based on sensitivity analysis.

* - Central estimate was calculated by doing a simple average of the Low and High estimate

Related links:

Statistical bulletin 2007: Figure PDU-1 part (i)

For more details see Tables PDU-1 to PDU-3 in the Statistical bulletin 2008.

See also ‘General notes for interpreting data’ on the Explanatory notes and help page

See also EMCDDA project (2003): National prevalence estimates of problem drug use in the European Union, 1995–2000, CT.00.RTX.23, EMCDDA, Lisbon, coordinated by the Institut für Therapieforschung, Munich.

Sources:

Reitox national focal points

(see the help page for information about formats etc.)

Page last updated: Thursday, 17 July 2008